ArticleSurgical endoscopy2026
Clinical outcomes of extensive endoscopic submucosal dissection involving more than three-fourths of the circumference for gastric epithelial neoplasia.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate the clinical outcomes of extensive submucosal dissection involving more than three-fourths of the circumference (eESD) for gastric epithelial neoplasia.
methodsConsecutive patients treated by eESD for gastric epithelial neoplasia were retrospectively included at 7 medical centers between 2015 and 2025. Short-term outcomes were en bloc resection, R0 resection, curative resection, procedure time, and adverse events, whereas long-term outcomes were local recurrence rate (LRR), simultaneous multiple carcinomas incidence rate (SMCIR), heterochronous multiple carcinomas incidence rate (HMCIR), and cancer metastasis incidence rate (CMIR).
resultsForty-three patients with 47 lesions (median tumor size: 6.0 cm) were analyzed. The en bloc resection, R0 resection, and curative resection rates were 100, 97.9, and 93.6%, respectively. The median procedure time was 115 min. Two patients had postoperative fever (4.7%) and two patients had delayed bleeding (4.7%). Postoperative abdominal pain occurred in 30 patients (69.8%). No patient occurred intraoperative and delayed perforations. Eight patients experienced post-eESD pyloric stenosis (18.6%). Within a median follow-up of 32.0 months, the LRR, SMCIR, HMCIR, and CMIR were 4.7, 2.3, 0.0, and 2.3%, respectively. Transverse extent of the mucosal defect more than 64 mm was a significant risk factor for post-eESD pyloric stenosis (OR: 15.99, 95% CI: 1.56-163.66, P = 0.017). Tumor depth of invasion (submucosal invasion depth ≥ 500 μm) was a significant risk factor for lymphovascular invasion (OR: 71.13, 95% CI: 3.03-1672.42, P = 0.008).
conclusioneESD for gastric epithelial neoplasia might be technically feasible and highly curative treatment.
Indexed as
Identifiers
41442046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.